best-in-bre tpo emerg initi
outperform pt
initi coverag dova pharmaceut outperform
rate pt dova biopharmaceut compani develop
relat defici midst commerci expans chronic immun
thrombocytopenia itp view doptelet best-in-bre therapi alreadi
defin commerci market billlion us itp market alon believ
strong commerci execut could re-rat dova share would come ahead
addit label expans option chemotherapy-induc thrombocytopenia
approv treatment patient tpo use
doptelet could win among tpo remain bread-and-butt
treatment varieti platelet disord physician commun
advoc tpo use off-label rituximab expect tpo market
remain stabl macro level said intern dynam could well-
suit doptelet carri improv safeti conveni
tpo market account approxim billion sale us
global market individu predominantli attribut itp market
rel evenli split promacta oral tpo nplate inject
carri host liabil believ imperfect product
profil posit doptelet take equal outsiz share
us itp label expans could initi ex-u deal opportun doptelet
current share level up-front payment partnership alon could
reflect substanti non-dilut capit infus compar made
europ asia said note rigel
tavaliss differenti mechan action tpo approach
afterthought consid near-term readout phase
studi indic could provid major lift share
beyond consid high unmet medic need popul consequ
low platelet count patient although long-term commerci
could gradual moat effect therapi could high
initi outperform pt sum-of-the-part ascrib
multipl valuat citp addit believ opportun
worth risk-adjust basi cld cash
equival make remaind valuat
year price histori dova
cld citp doptelet current
chemotherapy-induc
expect readout dova
found base
analyst certif import disclosur see disclosur
believ dova could reach signific commerci revenu
doptelet next month compani expand
chronic itp longer term addit opportun ex-u
chemotherapy-induc thrombocytopenia could re-rat
stock
phase studi read posit
doptelet achiev penetr chronic itp market
dova abl secur partner commerci doptelet
phase studi readout
quarterli execut doptelet commerci
potenti licens bd opportun ex-u market
us commerci itp launch reach greater share market
compani abl secur signific up-front payment
commerci right doptelet ex-u territori
regulatori approv ex-u territori occur faster expect
phase studi unsuccess
compani unabl partner commerci doptelet ex-u
us commerci launch slower anticip
appli revenu multipl itp estim peak revenu million million us
row respect model cld revenu opportun separ account approxim revenu
sum-of-the-part valuat ex-u territori ascrib royalti rate consid up-front payment conserv
upsid estim
appli discount rate dova valuat lower averag smid-cap biotech consid matur pipelin
commerci avail doptelet two three indic pt blend dcf multipl valuat
clinic efficaci doptelet fail meet clinic efficaci endpoint program
clinic safeti safeti signal emerg clinic studi doptelet
manufactur risk manufactur issu could limit penetr commerci market
regulatori risk regul rais addit requir concern around develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur develop asset could lower market potenti doptelet
negoti payor could limit market opportun itp cld and/or
financ dova may requir addit fund conduct addit studi commerci doptelet
commercial-stag biopharmaceut compani focus
treatment thrombocytopenia dova lead asset doptelet avatrombopag
thrombopoietin receptor agonist tpo-ra tpo design stimul platelet
product patient low unsaf level platelet doptelet current
approv chronic liver diseas patient undergo medic dental procedur
recent approv treat adult patient chronic immun thrombocytopenia
dova also conduct phase studi address thrombocytopenia cancer patient
undergo chemotherapi expect read
initi coverag outperform rate
price target next month valuat focus doptelet three
opportun chronic immun thrombocytopenia itp chronic liver diseas cld
chemotherapy-induc thrombocytopenia doptelet clinic profil posit
best-in-class thrombopoietin tpo receptor agonist class drug amount
billion revenu us alon
despit establish thrombocytopenia market treatment patient remain
fragment due variou liabil inconveni avail therapi
back recent label expans itp superior product profil anticip
doptelet achiev meaning share billion-dollar us market consid
option disrupt use tpo chronic liver diseas patient well expand
drug label cancer patient suscept thrombocytopenia due chemotherapi
usag bullish
consid dova current valuat believ nice setup diversifi catalyst lay
ahead focu quarterli execut itp phase readout potenti
announc ex-u licensing/bd deal around doptelet includ compani
current cash equival balanc million end ad option
compani agreement silicon valley bank see clear runway
value-cr event
employ composit valuat methodolog biotechnolog compani util
revenu multipl discount cash flow analysi consid dova commercial-
stage statu place greater weight dcf valuat compar multipl
analysi investor focu like rest commerci execut futur doptelet
dova price target assumpt indic exhibit
appli revenu multipl itp estim peak revenu million
million us row respect lie
lower rang industri averag instead ascrib high multipl expans
opportun model cld revenu opportun separ
account approxim revenu sum-of-the-part valuat ex-
us territori ascrib royalti rate consid up-front payment
conserv upsid estim
probabl success drug approv doptelet chemotherapy-induc
thrombocytopenia addit creat million revenu opportun could
also enhanc commerci drug ancillary-rel indic name
appli discount rate dova valuat lower averag smid-cap
biotech consid matur pipelin commerci avail doptelet
two three indic pt blend dcf multipl valuat
exhibit partsmultipl valuat per share
assumpt multipl tab itp growth ov termin valu cash outstand per share per share revenuemultipleyearwaccvaluationposrisk-adj valuat /share totalitp eu/row eu/row eu/row ye share dova outperform
exhibit partsmultipl valuat per share
risk thesi follow
clinic efficaci doptelet fail meet clinic efficaci endpoint
program
clinic safeti safeti signal emerg clinic studi doptelet
manufactur risk manufactur issu could limit penetr commerci
regulatori risk regul rais addit requir concern around
develop delay prevent regulatori approv
commercial/competitive/reimburs risk competit pressur
develop asset could lower market potenti doptelet negoti
payor could limit market opportun itp cld and/or
financ dova may requir addit fund conduct addit studi
thrombocytopenia three act
thrombocytopenia condit character defici platelet colorless
blood cell associ normal blood clot normal rang platelet count rest
platelets/l platelets/l platelet level fall low
normal phenotyp clot impair lead bruis purpura fatigu
splenomegali jaundic sever case platelets/l bleed
occur intern brain liver spleen fatal dova
thrombocytopenia focu includ immun thrombocytopenia thrombocytopenia relat
chronic liver diseas chemotherapy-induc thrombocytopenia
immun thrombocytopenia poorli understood itp character
idiopath natur howev time understand immun system role
play diseas becom elucid time theori around itp
focus platelet destruct mediat antibodi well impair
megakaryocyt involv product platelet altern approach
treatment includ target immun system includ b-cell target therapi
rituximab aggress surgeri splenectomi spleen associ
site b-cell matur sourc antibodi mediat platelet destruct
rang platelet itp patient count
blood reflect sever condit diseas origin diagnosi exclus
rule suspect caus low platelet count previous
refer purpura hemorrhag skin spot bleed medic commun
shift away aspect diseas present case
itp affect children adult howev therapi focus primarili adult
patient segment due overwhelm major pediatr case caus acut
reason infect commonli resolv without signific intervent
chronic liver diseas patient thrombocytopenia occur roughli three-quart
patient cirrhosi associ long time marker end-
stage diseas thrombocytopenia becom better understood patient
consequ depress platelet product sequestr platelet spleen
increas destruct platelet exhibit
exhibit pathophysiolog thrombocytopenia cld
mitchel et al hepat medicin evid research
hepat product thrombopoietin critic signal platelet product
perform parenchym sinusoid endotheli cell sever liver diseas
patient product greatli impair partli explain correl incid
thrombocytopenia patient later stage fibrosi stage patient
compar patient less sever diseas addit stress bone
marrow consumpt alcohol viral suppress depress product tpo
platelet lead impair level portal hypertens mainli due
mitchel et al hepat medicin evid research
chronic liver diseas increas flow platelet sequestr platelet
spleen lastli cld patient vulner caus platelet destruct via
stress vasculatur infect immune-medi complic combin
factor make challeng address thrombocytopenia patient
popul achiev long-term sustain platelet level
cytotox agent come host complic includ deplet variou
blood cell anemia thrombocytopenia neutropenia cytopenia
solid tumor rate develop thrombocytopenia report roughli
patient undergo chemotherapi roughli patient accord
manag approv treatment exist patient lead often dose reduct
chemotherapi delay chemotherapi treatment even cancel treatment
standard care restor platelet chronic itp remain steroid and/or ivig
address underli immun etiolog howev respons therapi
mix durabl respons observ first-lin treat patient
consid rather underwhelm efficaci vast major patient popul
requir second-lin later therapi moreov guidelin updat american
societi hematolog meet decemb long-term steroid use caution
particularli effect hypertens blood glucos increas chang
chronic itp use platelet transfus recommend advis
catastroph bleed case case surgeri due elev risk
arteri thrombosi well morbid mortal well short life span
day transfus platelet howev altern mode promot
thrombopoiesi explor primarili target tpo receptor
driver normal platelet product thombopoiesi exhibit
exhibit tpo receptor agonist target
imbach crowther nejm
restor normal platelet level attract pursuit due avoid
immun suppress addit drug target tpo receptor
led potenti advantag rout administr oral therapi
eltrombopag doptelet bind transmembran site tpo receptor
lead signal jak-stat map kinas pathway platelet product
exhibit tpo receptor agonist target
imbach crowther nejm
one off-label treatment chronic itp attent use rituximab
shown evid durabl respons one year howev due
off-label use immunosuppress effect medic commun note
stronger prefer tpo-ra medic panel priorit tpo rituximab
reduc toxic particularli earlier line provid
assess conduct itp market
neunert ce hematolog
chronic liver diseas patient thrombocytopenia approv option exist
includ dova doptelet shionogi mulpleta aim rais platelet count
ahead surgeri paradigm shift slow due physician prior use
transfus intervent greater awar follow commerci
launch comfort therapi could help bend product adopt curv
doptelet avatrombopag oral thrombopoietin receptor agonist design increas
platelet product consequ platelet count approv cld
thrombocytopenia adult patient chronic liver diseas schedul
undergo procedur recent itpthrombocytopenia adult patient chronic
immun thrombocytopenia insuffici respons previou
treatment doptelet sever distinguish product featur exhibit oral
tpo without food restrict strong toler profil believ compound
could first-in-class therapi target indic import note
conveni administr particular avoid food effect calcium rich diet
requir time hour certain meal could meaning improv
maintain complianc result commercial/real-world experi moreov
doptelet approv chronic liver diseas patient stress key safeti featur
distinguish altern tpo differenti could widen via result
due compel featur doptelet compar efficaci altern tpo
note fda approv expans drug label itp singl phase
studi addit two phase cld studi two phase itp studi previous
debat topic investor
valuat around itp upsid potenti
predomin market opportun doptelet rest chronic itp
establish billion market prior tpo therapi consid product profil
doptelet believ suffici support suggest doptelet potenti achiev
greater share market market penetr due improv safeti
cld approv black box warn conveni once-daili oral food
restrict dova plan target market target physician sale forc
profession us although opportun cld rel small
itp opportun view nontrivi context market capit
dova share current exhibit
exhibit revenu opportun doptelet
million
second bite cld appl
perform initi cld commerci launch challeng due sever
payor pushback due premium price doptelet rel mulpleta
shift commerci strategi target physician territori
rel price tpo-ra platelet transfus
follow itp approv believ dynam like reset doptelet
achiev prioriti posit market target averag price per pill
dova effect price cld anticip reduc two-third order
make way itp launch turn near-term financi perform expect
reset previous report revenu constant volum basi would cut
third consid chang ultim wac price doptelet cld
market transient disrupt reset potenti therapi indic
challeng commerci launch presenc lusutrombopag
mulpleta platelet transfus updat price afford new posit across
commerci market cld reli physician adopt tpo
broadli safer effect mean rais platelet count compar platelet
transfus ad tailwind oral cost effect therapi competit
platelet could long-term potenti market view
recent commerci launch doptelet cld amend conduct
exclus salix subsidiari bausch health intervent radiolog
hepatolog segment addit prior gastroenterolog colorect surgeri
proctolog segment part agreement dova pay percentag net sale
mid-thirti anticip dova focu remain itp commerci execut
come month
readout portfolio-level impact
dova conduct on-going phase studi avatrombopag
histori develop exhibit prior follow chemotherapi
treatment avatrombopag placebo random administ five daili
dose solid cancer patient cycl treatment patient observ
primari endpoint primari endpoint studi assess proport
patient achiev respons defin subject requir platelet
transfus dose reduct chemotherapi greater chemotherapi delay
expect phase top-lin data potenti support label
expans doptelet consid histor result tpo patient
chemotherapi induc thrombocytopenia believ probabl success
outcom rel high ascrib probabl success doptelet
eventu approv
success believ opportun could handili exceed cld revenu due
frequenc therapi twice cld anticip three cycl per patient prior
data conserv assum one cycl therapi per patient
enter dova enter period diversifi catalyst next
phase studi readout
quarterli execut doptelet commerci
potenti licens bd opportun ex-u market
beyond tpo-ra rituximab sever agent develop commerci
itp
efgartigimod argenx advanc efgartigimod phase studi itp
expect initi least one studi efgartigimod human fc
fragment design reduc igg antibodi associ platelet destruct two
phase studi evalu iv studi advanc sc formul iv induct
drug assess patient receiv platelet count respons least
first studi enrol patient efgartigimod also investig
gener myasthemia gravi gmg pemphigu vulgari pv chronic
random phase studi patient treat
efgartigimod period three week four dose achiev platelet count least
twice compar placebo patient exhibit
develop random phase studi
patient activ autoimmun hemolyt anemia immun
thrombocytopenia select immunoproteasom inhibitor investig
across multipl autoimmun diseas initi evid phase clinic studi
healthi volunt demonstr posit toler safeti place context
advers effect current market non-select proteasom inhibitor
tavaliss fostamatinib commerci tavaliss
treatment chronic itp patient insuffici respons previou treatment
approv may tavaliss spleen tyrosin kinas inhibitor focus
inhibit platelet phagocytosi destruct tavaliss gener
million quarterli product revenu fourth quarter launch despit
differenti mechan action tavaliss rel low respons rate
compar tpo inhibitor across two phase studi treatment tavaliss led
stabl platelet respons rate itp adult compar placebo
respect ns respect
oscotec develop random double-blind placebo-
control phase studi patient persist chronic immun
thrombocytopenia itp fail respond relaps prior therapi
platelet count oral inhibitor like tavaliss focus
block b-cell receptor signal fcr signal spleen tyrosin kinas
intracellular non-receptor cytoplasm protein tyrosin kinas serv key
mediat fc receptor cell receptor signal inflammatori cell
hutchison medipharma develop random doubl
blind placebo-control phase studi adult patient immun
thrombocytopenia trial consist two stage dose escal stage dose
expans stage novel select small molecul oral inhibitor
hetrombopag olamin jiangsu hengrui medicin develop hetrombopag olamin
random double-blind four-stag phase studi patient
chronic previous treat itp patient administ dose-adjust
hetrombopag olamin mg/day maintain platelet count
hetrombopag olamin hetrombopag novel small-molecul oral bioavail non-
develop phase studi
healthi volunt patient itp part healthi
volunt respect place adouble-blind placebo-control singl
ascend dose protocol part itp patient receiv ivig cross-ov
dose design subsequ part itp patient receiv multipl dose
primari endpoint studi assess platelet respons hypersialyl
human immunoglobulin aim enhanc potenc rel convent ivig
sutimlimab bioverativ subsidiari sanofi sni develop
phase studi patient chronic itp human
monoclon antibodi target serin proteas within
involv classic complement cascad activ compon immun
system classic complement pathway key mechan involv cytopenia
design select inhibit diseas process upstream classic
complement pathway without affect altern lectin complement pathway
inc develop open-label phase
studi patient relapsed/refractori itp patient platelet count
oral small molecul revers coval btk inhibitor
design inhibit cell activ block antibodi mediat activ
commercial-stag late development-stag compani dova focus
market develop doptelet requir capit execut fund
oper dova conduct initi public equiti offer subsequ secondari
offer june dova rais total gross amount approxim million
million common share per share
follow ipo dova rais addit gross proce million februari
underwritten public offer million share price
june compani hold cash equival balanc million
believ provid cash runway may dova enter
amend restat loan agreement silicon valley bank svb extend
interest period exist million loan facil month provid
addit potenti borrow million upon achiev certain clinic revenu
mileston juli subsequ quarter-end dova drew million
loan agreement upon approv itp dova report option vest
exercis includ valuat model model futur capit rais
order support futur commerci doptelet develop separ
david zaccardelli pharm presid chief execut offic
dr zaccardelli join presid ceo decemb
prior join dova serv act chief execut offic cempra inc
decemb compani merger inc novemb
dr zaccardelli serv sever senior manag role
offic execut vice presid pharmaceut develop oper prior
join dr zaccardelli found led start-up compani focus
contract pharmaceut develop servic
dr zaccardelli work burrough wellcom co glaxo wellcom inc
varieti clinic research posit also serv director clinic scientif
affair bausch dr zaccardelli current
serv board director melinta well evecxia inc corerx inc
privat held compani dr zaccardelli receiv pharm univers
michigan complet fellowship clinic research drug develop
univers north carolina burrough wellcom co
mr hahn join dova chief offic januari previous
execut vice presid chief financi offic cempra inc februari
novemb mr hahn chief financi offic
corp agricultur biotechnolog compani lead merger bayer cropscienc
serv financ director prior mr hahn chief
financi offic variou compani includ gigabeam corpor
telecommun equip compani buildlink inc performawork inc
softwar compani charl colvard ltd consum product compani mr
hahn began career ernst young serv variou capac
culmin senior manag mr hahn hold
account financ univers wisconsin-milwauke certifi
public account state maryland north carolina
dr allen serv chief medic offic sinc april twenti year
pharmaceut develop experi success led develop
approv five new hematolog oncolog product januari april
dr allen serv chief medic offic manag clinic develop medic
affair regulatori affair argo dr allen serv chief medic
offic march januari august
march dr allen serv chief medic offic
dr allen serv clinic head global oncolog
therapeut area director research develop site
cambridg dr allen help establish oncolog new
therapeut area serv execut director area
leader ann arbor oncolog portfolio dr allen hold ph
rutger biomed formerli univers medicin
dentistri new jersey complet resid train intern medicin
fellowship train hematolog oncolog duke univers medic center
mr hoitt join dova chief commerci offic prior dova jason vice-president head
us sale inc may decemb prior join
jason spent four year held leadership role
medic affair us sale launch exondi previous jason held senior
posit market sale play
integr role launch incivek jason
varieti role increas respons culmin lead role launch
viread hbv jason began career bench research boston new england
medic center tuft medic school led biopharmaceut role
astrazeneca schere oncology-biotech jason hold colleg
holi cross worcest
dr lalibert join dova sr vice presid product develop march
respons manag clinic pharmaceut develop well
commerci suppli chain function dr lalibert held role
increas respons unit therapeut corpor includ
sr vice presid product develop clinic oper
respons develop activ preclin phase includ
prepar regulatori submiss dr lalibert receiv pharm
univers michigan complet drug develop fellowship univers
north carolina school pharmaci glaxosmithklin
stock price compani mention report
amgen inc amgn-nasdaq rate op jay olson
statement oper
thousand except per share
product sale
research develop licens acquir
research develop
sell gener administr
interest incom incom net
incom tax
comprehens loss net tax
net loss per common share basic dilut
weight average common share basic dilut
thousand
cash equival
prepaid expens current asset
furnitur equip net
liabil stockhold equiti
due relat parti
current portion oper leas liabil
current portion long-term debt
current portion defer revenu
seri prefer stock par valu share author share issu outstand june decemb
undesign prefer stock par valu share author share issu outstand march decemb respect
prefer stock par valu share author share issu outstand septemb decemb respect
common stock par valu share author share issu outstand june decemb
common stock par valu share author share issu outstand septemb decemb respect
common stock par valu share author share issu outstand march decemb respect
common stock par valu share author share issu outstand march decemb respect
addit paid capit
total liabil stockhold equiti
statement cashflow
thousand
research development-licens acquir expens
non-cash research develop expens
loss dispos furnitur equip
amort debt discount debt issuanc cost
chang oper asset liabil
due relat parti
net cash use oper activ
purchas fix asset
purchas furnitur equip
net cash use invest activ
payment note payabl
proce exercis stock option
proce issuanc debt
proce earli exercis stock option relat parti
proce issuanc common stock connect
payment offer cost connect ipo
proce issuanc common stock
payment offer cost connect issuanc common
net cash provid financ activ
net increas decreas cash equival
cash equival begin period
cash equival end period
patient citp
patient refractori steroids/ivig
itp patient treat doptelet
patient itp
patient refractori steroid
citp patient treat doptelet
adult us
patient chronic liver diseas cld
cld patient thrombocytopenia
patient cld undergo procedur
cld patient treat doptelet
adult eu
patient chronic liver diseas cld
cld patient thrombocytopenia
patient cld undergo procedur
ga patient treat
chemotherapi patient us
chemotherapi patient solid tumor
chemotherapi patient thrombocytopenia
patient treat doptelet
annual us price rel cld
chemotherapi patient us
chemotherapi patient solid tumor
chemotherapi patient thrombocytopenia
patient treat doptelet
eu price rel cld
